Search
EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Syndromes
The second scientific meeting on EHA-SWG Scientific Meeting on Granulocytes and Constitutional Marrow Failure Disorders and Leukemia Predisposing Genes was held on October 10-12, 2019 in Prague, Czech Republic.
Read moreWithout access to treatment, can we truly innovate in rare diseases?
Interview with Giampaolo Merlini
There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.
Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013
About the EHA Annual Congress
Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.
EHA24 is YOUR congress – here’s how you can make the most of it
Congress season is an exciting time for any field. It’s a time when experts come together to share the latest developments, and also an opportunity to see friends and colleagues who you haven’t seen in a while.
Read moreEU Calls for Proposal 2022
Introduction
Spurred by COVID-19 and rising challenges to the financial sustainability of Europe’s health systems, a flurry of new EU policies and programs in health has sprung up since last year.
EHA Award winners put in the spotlight in Copenhagen
The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.
Read moreEHA Kick-off Grant review and selection process
1. Eligibility checkAfter the deadline has passed, we'll check your application for completion and compliance with the eligibility criteria.
Read moreT2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy
This press release is originally found here: http://prn. to/2YF7Js3
THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- »